Joachim M Baehring, MD

Professor of Neurology; Clinical Program Leader, Brain Tumor Program, Smilow Cancer Hospital

Clinical Interests

  • Brain Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Neurology: Brain Tumors

Neurosurgery

Cancer Center: Brain Tumor Program | Hematology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Neurology AB of Psychiatry & Neurology (2001)

Clinical Trials

Conditions Study Title
Brain and Nervous System A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548
Brain and Nervous System A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Brain and Nervous System A Phase III Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Brain and Nervous System A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)
Brain and Nervous System A Phase II/III Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Brain and Nervous System, Colon, Kidney, Rectum INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients
Brain and Nervous System, Phase I A Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)

Edit this profile

Contact Info

Joachim M Baehring, MD
Patient Care Locations
Yale Brain Tumor ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 8th Floor Multispecialty Care Center

New Haven, CT 06511
View on map...
Greenwich Hospital 77 Lafayette Place
Greenwich, CT 06830
View on map...
Mailing Address
Neuro-Oncology 15 York Street LLCI 920
PO Box 208028

New Haven, CT 06520-8082